| | | | | | | | | | | | | | | | |
| |
| Issue Date FY: 2024 ( Subtotal = $170,343,336 ) (Continued on the next page) |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA243328 | Tumor-specific autoantibodies for SCLC early detection | 001 | 6 | NIH | 4/15/2024 | $21,374 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R37CA234488 | Role of tumor cell cluster-induced signaling in breast cancer metastasis | 000 | 6 | NIH | 11/22/2023 | $362,340 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R37CA234488 | Role of tumor cell cluster-induced signaling in breast cancer metastasis | 001 | 6 | NIH | 4/15/2024 | $20,131 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI150500 | Mathematical modeling of optimal therapeutic combinations for HIV cure | 000 | 6 | NIH | 11/6/2023 | $419,297 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R37CA240832 | Novel Approaches to CD33-Directed Radioimmunotherapy | 001 | 6 | NIH | 4/17/2024 | $43,430 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R37CA240832 | Novel Approaches to CD33-Directed Radioimmunotherapy | 000 | 6 | NIH | 11/15/2023 | $781,727 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01HL148565 | Clonal Hematopoiesis in the Women's Health Initiative | 001 | 6 | NIH | 4/1/2024 | $815,981 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UG1CA233328 | Hutchinson Center as Lead Academic Participating Site (UG1) | 001 | 6 | NIH | 4/18/2024 | $24,778 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UG1CA233328 | Hutchinson Center as Lead Academic Participating Site (UG1) | 000 | 6 | NIH | 2/13/2024 | $442,472 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R37CA230617 | Hormone signaling and translation control in advanced prostate cancer | 000 | 7 | NIH | 1/5/2024 | $390,548 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI140891 | Complete mapping of immune selection from antibodies to HIV | 000 | 7 | NIH | 12/14/2023 | $362,442 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA227092 | Novel Intervention Approaches to Alleviate Allogeneic Transplant-Related Morbidity and Mortality | 001 | 6 | NIH | 4/17/2024 | $42,607 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA227092 | Novel Intervention Approaches to Alleviate Allogeneic Transplant-Related Morbidity and Mortality | 000 | 6 | NIH | 1/30/2024 | $766,928 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA231838 | Immunogenetics of Outcomes Disparities After Allogeneic HCT | 000 | 8 | NIH | 4/4/2024 | $424,151 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI136946 | Mechanisms and consequence of helical shape generation in Helicobacter pylori | 001 | 7 | NIH | 3/27/2024 | $559,231 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R13OD024033 | Annual HVTN Translational HIV Early Stage Investigator (ESI) Conference | 000 | 8 | NIH | 3/29/2024 | $60,000 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01HL136135 | Multiplex base/prime editors for in vivo selection of modified HSPCs in hemoglobinopathy | 000 | 9 | NIH | 1/15/2024 | $669,225 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R35GM118120 | Molecular analysis of genetic recombination and DNA break repair | 000 | 10 | NIH | 4/10/2024 | $873,974 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U10CA180819 | SWOG Statistics and Data Management Center | 002 | 11 | NIH | 4/17/2024 | $401,127 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U10CA180819 | SWOG Statistics and Data Management Center | 001 | 11 | NIH | 3/4/2024 | $7,220,289 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI069481 | Seattle-Lausanne Clinical Trials Unit | 000 | 19 | NIH | 11/2/2023 | $205,688 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI069481 | Seattle-Lausanne Clinical Trials Unit | 000 | 19 | NIH | 11/2/2023 | $607,963 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 009 | 19 | NIH | 3/21/2024 | $9,774,635 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 009 | 19 | NIH | 3/21/2024 | $699,895 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 009 | 19 | NIH | 3/21/2024 | $250,000 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 003 | 19 | NIH | 11/14/2023 | $9,774,636 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 003 | 19 | NIH | 11/14/2023 | $699,896 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 003 | 19 | NIH | 11/14/2023 | $250,000 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | HIV Vaccines Clinical Trials Network Leadership and Operations Center | 003 | 19 | NIH | 11/14/2023 | $500,000 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | SDMC: HIV Vaccine Trials Network | 005 | 19 | NIH | 4/18/2024 | $0 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | SDMC: HIV Vaccine Trials Network | 005 | 19 | NIH | 4/18/2024 | $0 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068618 | HIV Vaccine Trials Network Laboratory Center | 007 | 19 | NIH | 3/20/2024 | $9,067,448 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068618 | HIV Vaccine Trials Network Laboratory Center | 007 | 19 | NIH | 3/20/2024 | $6,336,305 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | SDMC: HIV Vaccine Trials Network | 004 | 19 | NIH | 4/4/2024 | $9,074,979 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068618 | HIV Vaccine Trials Network Laboratory Center | 000 | 19 | NIH | 11/8/2023 | $9,067,449 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068618 | HIV Vaccine Trials Network Laboratory Center | 000 | 19 | NIH | 11/8/2023 | $3,836,305 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068618 | HIV Vaccine Trials Network Laboratory Center | 000 | 19 | NIH | 11/8/2023 | $400,000 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | SDMC: HIV Vaccine Trials Network | 004 | 19 | NIH | 4/4/2024 | $6,921,264 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068617 | SDMC: HIV Prevention Trials Network | 002 | 19 | NIH | 4/2/2024 | $3,483,528 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068617 | SDMC: HIV Prevention Trials Network | 002 | 19 | NIH | 4/2/2024 | $5,399,174 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068617 | SDMC: HIV Prevention Trials Network | 002 | 19 | NIH | 4/2/2024 | $1,077,254 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068617 | SDMC: HIV Prevention Trials Network | 001 | 19 | NIH | 3/5/2024 | $1,195,111 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | SDMC: HIV Vaccine Trials Network | 001 | 19 | NIH | 11/16/2023 | $9,074,980 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068617 | SDMC: HIV Prevention Trials Network | 000 | 19 | NIH | 11/14/2023 | $3,483,529 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068617 | SDMC: HIV Prevention Trials Network | 000 | 19 | NIH | 11/14/2023 | $966,346 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068635 | SDMC: HIV Vaccine Trials Network | 001 | 19 | NIH | 11/16/2023 | $6,921,265 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068617 | SDMC: HIV Prevention Trials Network | 000 | 19 | NIH | 11/14/2023 | $5,399,174 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068617 | SDMC: HIV Prevention Trials Network | 000 | 19 | NIH | 11/14/2023 | $1,077,255 |
| 2024 | 2024 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U01AI069197 | Hematopoietic Stem Cell And Cord Blood Transplantation | 000 | 21 | NIH | 4/17/2024 | $200,000 |
|